Exploring federal cannabis rescheduling delays, tightened Texas hemp limits, and Massachusetts' adult-use repeal initiative.

As federal delays reshape cannabis financing, operators find resilience in beverage growth and restructuring strategies.

A new DEA registration pathway pulls state-licensed medical cannabis manufacturers, distributors, and labs into the federal Schedule III framework—potentially easing 280E tax pain.

Treasury and the IRS say tax guidance tied to cannabis rescheduling is a top priority for 2026–2027, with big implications for Section 280E and mixed medical/adult-use operators.

High Times spotlights four cannabis attorneys navigating 280E taxes, the trademark gap, Farm Bill fallout, and the moral cost of building an industry while people remain incarcerated.

The Department of Justice reschedules medical cannabis to Schedule III and schedules June 2026 hearings on adult-use reform. Here is what it means.

NCIA’s 14th Lobby Days landed after DOJ’s April order moving state‑regulated medical cannabis to Schedule III. Here’s what Congress heard—and what DMV consumers and delivery operators should watch.